These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35012940)

  • 1. Functional impact and targetability of
    Choo F; Odintsov I; Nusser K; Nicholson KS; Davis L; Corless CL; Stork L; Somwar R; Ladanyi M; Davis JL; Davare MA
    Cold Spring Harb Mol Case Stud; 2022 Jan; 8(1):. PubMed ID: 35012940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood.
    Ting MA; Reuther J; Chandramohan R; Voicu H; Gandhi I; Liu M; Cortes-Santiago N; Foster JH; Hicks J; Nuchtern J; Scollon S; Plon SE; Chintagumpala M; Rainusso N; Roy A; Parsons DW
    J Pathol; 2021 Sep; 255(1):52-61. PubMed ID: 34086347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes.
    Rekhi B; Upadhyay P; Ramteke MP; Dutt A
    Mod Pathol; 2016 Dec; 29(12):1532-1540. PubMed ID: 27562493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: evidence for a common pathogenesis.
    Agaram NP; Chen CL; Zhang L; LaQuaglia MP; Wexler L; Antonescu CR
    Genes Chromosomes Cancer; 2014 Sep; 53(9):779-87. PubMed ID: 24824843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expanding morphological and genetic spectrum of MYOD1-mutant spindle cell/sclerosing rhabdomyosarcomas: a clinicopathological and molecular comparison of mutated and non-mutated cases.
    Tsai JW; ChangChien YC; Lee JC; Kao YC; Li WS; Liang CW; Liao IC; Chang YM; Wang JC; Tsao CF; Yu SC; Huang HY
    Histopathology; 2019 May; 74(6):933-943. PubMed ID: 30604891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification.
    Agaram NP; LaQuaglia MP; Alaggio R; Zhang L; Fujisawa Y; Ladanyi M; Wexler LH; Antonescu CR
    Mod Pathol; 2019 Jan; 32(1):27-36. PubMed ID: 30181563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transactivating mutation of the MYOD1 gene is a frequent event in adult spindle cell rhabdomyosarcoma.
    Szuhai K; de Jong D; Leung WY; Fletcher CD; Hogendoorn PC
    J Pathol; 2014 Feb; 232(3):300-7. PubMed ID: 24272621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment and characterization of NCC-ssRMS2-C1: a novel patient-derived cell line of spindle cell/sclerosing rhabdomyosarcoma.
    Tsuchiya R; Yoshimatsu Y; Noguchi R; Sin Y; Ono T; Sei A; Takeshita F; Sugaya J; Nakatani F; Yoshida A; Ohtori S; Kawai A; Kondo T
    Hum Cell; 2021 Sep; 34(5):1569-1578. PubMed ID: 34164773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytogenetic and Molecular Study of an Adult Sclerosing Rhabdomyosarcoma of the Extremity:
    Gorunova L; Bjerkehagen B; Micci F; Heim S; Panagopoulos I
    Cancer Genomics Proteomics; 2020; 17(5):563-569. PubMed ID: 32859634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological Role and Clinical Implications of
    Di Carlo D; Chisholm J; Kelsey A; Alaggio R; Bisogno G; Minard-Colin V; Jenney M; Dávila Fajardo R; Merks JHM; Shipley JM; Selfe JL
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.
    Kohsaka S; Shukla N; Ameur N; Ito T; Ng CK; Wang L; Lim D; Marchetti A; Viale A; Pirun M; Socci ND; Qin LX; Sciot R; Bridge J; Singer S; Meyers P; Wexler LH; Barr FG; Dogan S; Fletcher JA; Reis-Filho JS; Ladanyi M
    Nat Genet; 2014 Jun; 46(6):595-600. PubMed ID: 24793135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrigendum: Functional impact and targetability of
    Choo F; Odintsov I; Nusser K; Nicholson K; Davis L; Corless CL; Stork L; Somwar R; Ladanyi M; Davis JL; Davare MA
    Cold Spring Harb Mol Case Stud; 2022 Apr; 8(3):. PubMed ID: 35483883
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytomorphology of spindle cell/sclerosing rhabdomyosarcoma, including MYOD1 (LI22R) mutation result.
    Rekhi B; Dodd L; Dharavath B; Dutt A
    Diagn Cytopathol; 2022 Dec; 50(12):E367-E372. PubMed ID: 35929754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
    Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y
    PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and Characterization of a Sclerosing Spindle Cell Rhabdomyosarcoma Cell Line with a Complex Genomic Profile.
    Schleicher S; Grote S; Malenke E; Chan KC; Schaller M; Fehrenbacher B; Riester R; Kluba T; Frauenfeld L; Boesmueller H; Göhring G; Schlegelberger B; Handgretinger R; Kopp HG; Traub F; Boehme KA
    Cells; 2020 Dec; 9(12):. PubMed ID: 33322555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment and characterization of NCC-ssRMS1-C1: a novel patient-derived spindle-cell/sclerosing rhabdomyosarcoma cell line.
    Yoshimatsu Y; Noguchi R; Tsuchiya R; Sei A; Sugaya J; Iwata S; Sugiyama M; Yoshida A; Kawai A; Kondo T
    Hum Cell; 2020 Jul; 33(3):886-893. PubMed ID: 32300959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYOD1 as a prognostic indicator in rhabdomyosarcoma.
    Ahmed AA; Habeebu S; Farooqi MS; Gamis AS; Gonzalez E; Flatt T; Sherman A; Surrey L; Arnold MA; Conces M; Koo S; Dioufa N; Barr FG; Tsokos MG
    Pediatr Blood Cancer; 2021 Sep; 68(9):e29085. PubMed ID: 33913590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.
    Meric-Bernstam F; Akcakanat A; Chen H; Do KA; Sangai T; Adkins F; Gonzalez-Angulo AM; Rashid A; Crosby K; Dong M; Phan AT; Wolff RA; Gupta S; Mills GB; Yao J
    Clin Cancer Res; 2012 Mar; 18(6):1777-89. PubMed ID: 22422409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.